A nationwide recall is underway for one lot of Tyenne, an injectable medicine used to control inflammation in rheumatoid arthritis and several other conditions, after the manufacturer found glass particles inside the vials. Fresenius Kabi announced the action on August 10, and the U.S. Food and Drug Administration posted the company announcement the next day. The recall is at the user level, meaning hospitals, infusion centers, and clinics are being asked to pull the product and return it.
This is not a pill a patient can set aside. Tyenne is given intravenously, so anything in the vial goes directly into a vein. Regulators treat particulate contamination in an injectable differently from a labeling error.
The affected group is narrow but medically vulnerable. People who receive tocilizumab infusions are generally living with active autoimmune disease, and many have already tried other treatments without adequate relief.
The Lot Number Infusion Centers Need to Pull
The recall covers Tyenne (tocilizumab-aazg) Injection, 400 mg per 20 mL, in 20 mL vials. The identifying details are lot number 16UI07, National Drug Code 65219-594-20, product code 590120, and an expiration date of August 2028. The company reported that the affected units were shipped between March 3 and March 25 of this year.
Distribution was nationwide, to wholesalers, distributors, and direct customers. Fresenius Kabi said it is notifying distributors and customers by letter and arranging returns, and it has asked health care facilities holding the lot to stop distributing, dispensing, or using it immediately.
Only that single lot is covered. Other lots of Tyzenne and other tocilizumab products are not part of this action. The action appears alongside other current entries on the FDA's list of recalls and safety alerts.
Risks Tied to Particles in an Intravenous Medicine
The company's risk statement describes a range of possible consequences. At the milder end, administering a product containing glass particulates may cause "local irritation, pain, or swelling at the infusion site," along with vein inflammation.
The more serious scenarios described in the announcement involve particles causing blockage and clotting in blood vessels. That can cut off blood flow to vital organs, and the company specifically named the possibility of a life-threatening blood clot in the lungs, permanent organ damage, or death.
Those are described as potential consequences of the defect, not reported outcomes. No injuries linked to this lot have been announced. That distinction matters, because recall language is written to describe the worst plausible outcome rather than what has actually happened.
Patients Who Depend on Tocilizumab Infusions
Tyenne is approved for adults with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more disease-modifying antirheumatic drugs, and for adults with giant cell arteritis. It is also approved for patients aged 2 and older with active polyarticular or systemic juvenile idiopathic arthritis, for adults and children aged 2 and older with severe or life-threatening cytokine release syndrome induced by CAR T-cell therapy, and for certain hospitalized adults with COVID-19.
That range means the recall touches pediatric rheumatology clinics, cancer centers, and hospital inpatient pharmacies, not only adult arthritis practices. Families of children receiving infusions for juvenile idiopathic arthritis are among those who may want to ask which lot their child received.
The practical risk to any individual patient depends on whether their infusion came from lot 16UI07. Most did not. Because the shipping window closed in March, much of the lot has likely already been used or moved through inventory, which is why the recall is directed at facilities rather than households.
Questions Worth Asking Before the Next Infusion
Patients do not hold these vials at home, so the checking falls to clinics and pharmacies. Still, anyone scheduled for a tocilizumab infusion can reasonably ask their infusion center whether it stocked the recalled lot and whether it has been removed.
Anyone who has already received an infusion and experienced related problems should contact their physician or health care provider, as the company advised. Symptoms that would warrant prompt attention include new pain, swelling or redness at the infusion site, or sudden shortness of breath or chest pain, which need urgent evaluation.
Patients should not stop a prescribed biologic on their own. Interrupting treatment for rheumatoid arthritis or giant cell arteritis carries risks, including disease flares, and any change should be made under the guidance of the prescribing clinician.
Fresenius Kabi listed a quality assurance line for recall questions at 1-866-716-2459, available on weekdays. Problems can also be reported online through the FDA's MedWatch program, or by mail or fax using a downloadable reporting form.
The FDA maintains a running list of drug recalls, with further updates appearing there. The agency posts company announcements as a public service and does not endorse the product or firm.
Key Questions Answered
Which product is being recalled? One lot of Tyenne (tocilizumab-aazg) Injection, 400 mg per 20 mL, in 20 mL vials. The lot number is 16UI07, with National Drug Code 65219-594-20 and an expiration date of August 2028.
Why was the recall issued? An internal investigation at Fresenius Kabi found that the product contained glass particles. Injectable medicines must be free of particulate matter because anything in the vial enters the bloodstream directly.
Have people been harmed? No injuries tied to this lot have been announced. The risks described in the recall notice are potential consequences of the defect, not reported cases.
Who receives this medication? Adults with rheumatoid arthritis or giant cell arteritis, patients aged 2 and older with certain forms of juvenile idiopathic arthritis, patients with CAR T cell-induced cytokine release syndrome, and some hospitalized adults with COVID-19.
Should patients stop treatment? No one should stop a prescribed biologic without speaking to their clinician. Stopping treatment can allow autoimmune disease to flare. The appropriate step is to ask the infusion center about the lot.
What symptoms warrant medical attention? Pain, swelling, or redness at an infusion site should be reported to a clinician. Sudden shortness of breath or chest pain requires urgent evaluation.
Where can problems be reported? Adverse reactions or quality problems can be submitted to the FDA's MedWatch program, or to Fresenius Kabi Medical Affairs and Vigilance at 1-800-551-7176 on weekdays.
